novo nordisk - Search News

News

Novo Nordisk is no longer a buy

Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said on Tuesday.

The Motley Fool on MSN · 1h

What's Going On With Novo Nordisk Stock?

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

MarketBeat on MSN · 3h

Novo Nordisk Stock Sinks-But Is a Bottom Finally In?

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than 43% in 2025.

Novo Nordisk stock downgraded as Trump teases 250% pharma tariffs

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

21hon MSN

Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...

1don MSN

How Novo Nordisk Gave Up Its Weight-Loss Gains

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

6don MSN

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

24/7 Wall St.6d

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk to Disclose Full Second-Quarter Earnings Amid Management Reshuffle -- Earnings Preview

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

1don MSN

Bernstein Maintains a Hold Rating on Novo Nordisk (NVO)

Novo Nordisk A/S (NYSE: NVO) is one of the top cheap pharmaceutical stocks to buy now. On August 1, Bernstein analyst Florent ...

Fierce Pharma7d

Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...